Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Italy / NCT06706973
Recruiting Observational

Profiling and Targeting Epigenetic Marks to Improve Diagnosis and Therapeutic Approaches in Head and Neck Cancer

NCT06706973 · tracked via the Priya Life Science Italy tracker
Sponsor
European Institute of Oncology
Phase
Observational
Started
2024-03-06
Last updated
2024-11-27

Condition(s) studied

Head and Neck Cancer

Study summary

Investigators have recently shown that epigenetic remodelling enzymes, such as HDAC inhibitors, are feasible drugs in HNC (8, 9). Preliminary data are indicating some deregulated epigenetics marks suggesting the corresponding histone modifiers as possible targets for the treatment of HNC, providing an attractive and feasible option to build upon. Our overarching hypothesis is that unique histone marks distinguish HPV+ and HPV- HNC and that specific histone modifiers are novel mediators of HNC tumorigenesis in an HPV specific manner

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:• Age: Adults aged ≥ 18 years diagnosed with HNC * Sex: Both male and female * Human papilloma virus (HPV) test: Both positive and negative. * Tumor: primary tumors, treatment naïve, squamous cell carcinoma * Cancer stage: I-IV * Anatomic location: oral cavity, larynx, oropharynx * Tumor fragments not required for diagnostics Exclusion Criteria: * Previous radiotherapy, chemotherapy or immunotherapy for HNC * Unable to provide written informed consent

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
European Institute of oncology Milan MI Recruiting

More European Institute of Oncology trials in Italy

Psychological Assessment in Patients Treated with Spinal Cord Stimulation Recruiting
Vabb After Neoadjuvant Therapy to Avoid Surgery-pCR to Avoid Breast Surgery Recruiting
Real-WorlD ZolbetUximab in Patients With HER-2 Negative and CLaudin 18.2 PosItive MetastatiC AdEnocarcinoma Recruiting
Dietary Quality and Nutritional Adequacy Among Vegetarians Attending the European Institute of Oncology Recruiting
EpigenOMic Determinants of the Neuroendocrine Phenotype As Biomarkers for Neuroendocrine Neoplasms Recruiting

Other trials for the same condition

Effect of Prehabilitation on Head and Neck Cancer Patients Recruiting
The Head and Neck Registry of the European Reference Network on Rare Adult Solid Cancers Recruiting
Psychological and Psychiatric prOfile in Glioblastoma and Head and Neck Cancer Recruiting
HRQoL in Patients With Solid Tumors Treated With Hadrontherapy Recruiting
Stereotactic Body Radiotherapy in Patients With Rare Oligometastatic Cancers (OligoRARE) Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06706973 on ClinicalTrials.gov ↗ ← All trials in Italy